52 Week Range
As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay
July 6 (Reuters) - ASKA Pharmaceutical Co Ltd <4514.T>:Says it voluntarily recalls hypertension treatment drug valsartan 20mg・40mg・80mg・160mgAA from July 5 .
May 31 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it and ASKA Pharmaceutical Co Ltd <<<4514.T>>> announced today that they entered inter a licensing agreement to grant ASKA exclusive commercialization right for uterine fibroids and exclusive development and commercialization rights for endometriosis for Japan to maximize the product value of Takeda-owned relugolix.Based on this agreement, Takeda will receive upfront payment for granting the exclusive commercialization right for uterine fibroids and the exclusive development and commercialization rights for endometriosis in Japan as well as holding the right to receive royalties on sales.
April 16 (Reuters) - ASKA Pharmaceutical Co Ltd <4514.T>:Says it will set up a pharmaceutical JV with Omnicare Drugs India Private Limited, in India, in May .Says the JV will be capitalized at $12.5 million .Says it will hold 30 percent stake in the JV .
ASKA Pharmaceutical Co Ltd <4514.T> :Says the company enters into an exclusive option agreement with Pieris Pharmaceuticals on development and sale of anemia treatment drug PRS-080 in Japan, Korea and other Asian countries.
Pieris Pharmaceuticals Inc <PI6.F> : Pieris signs partnership for anemia drug PRS-080, granting exclusive option in Japan to Aska Pharmaceutical . Pieris Pharmaceuticals Inc - co will receive an immediate option payment of $2.75 million usd from Aska . Pieris Pharmaceuticals Inc - a Phase 1 study conducted in healthy volunteers demonstrated that a single dose of PRS-080 was well tolerated . Pieris Pharmaceuticals Inc - Pieris may also receive double-digit royalties on net sales of PRS-080 up to mid- to high-teens . Pieris Pharmaceuticals Inc - PRS-060, anticipated to begin a first-in-human study around middle of 2017 . Pieris Pharmaceuticals Inc - PRS-343 scheduled to enter a first-in patient trial in first half of 2017 .Pieris Pharmaceuticals - should Aska exercise option, Pieris would be eligible for over $80 million usd in combined option exercise fee and milestones.
ASKA Pharmaceutical Co Ltd <4514.T> :Says enters into an exclusive cooperation contract TesoRx Pharma LLC on development and sale of THG-1001 in Japan.
ASKA Pharmaceutical <4514.T> :Says it forms business alliance with Nobelpharma Co Ltd, regarding ethical pharmaceuticals of maternity and gynaecology field.
ASKA Pharmaceutical Co Ltd:Says the company lowered the consolidated full-year outlook for revenue to 43,210 mln yen from 44,000 mln yen for FY ended March 2016.Sees an increased operating profit forecast to 1,160 mln yen from 800 mln yen.Sees an increased ordinary profit forecast to 1,520 mln yen from 1,000 mln yen.Sees an increased net profit forecast to 700 mln yen from 600 mln yen.Sees an increased earnings per share to 25.15 yen from 21.53 yen per share.Comments reduced costs is the main reason for the forecast.
ASKA Pharmaceutical Co Ltd:Says signed commercialization contract for a treatment of hypertension with Takeda Pharmaceutical on Feb. 24.Says ASKA Pharmaceutical obtain manufacturing and marketing approval for the treatment of hypertension from the Ministry of Health, Labour and Welfare in February.
ASKA Pharmaceutical Co Ltd:Says the company lowered the consolidated full-year outlook for the FY ending March 2016.Revenue forecast decreased to 44,000 million yen from 47,000 million yen.Operating profit forecast decreased to 800 million yen from 2,000 million yen.Ordinary profit forecast decreased to 1,000 million yen from 2,200 million yen.Net profit forecast decreased to 600 million yen from 1,600 million yen.Earnings per share decreased to 21.53 yen from 57.44 yen.Comments that delay of new product and sales lower than expected are the main reasons for the forecast.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.